RetinaLogik Secures $1.1M Funding and Health Canada Approval for VR-AI Eye Care Platform
核心洞察
RetinaLogik (搜索) Inc. has raised $1.1 million in funding and received Health Canada Class II medical device approval for its VR-AI-powered eye care platform, enabling more efficient visual field exams.
The Calgary-based startup's technology reduces equipment costs by up to 90% compared to traditional systems while offering enhanced patient comfort through a portable headset design.
The ISO-13485 and MDSAP certified device, which is also FDA registered, features multilingual support and aims to expand across North America to improve early detection of vision-threatening conditions.
Calgary-based RetinaLogik (搜索) Inc. has successfully secured $1.1 million in funding while simultaneously obtaining Health Canada's Class II medical device approval for its innovative virtual reality and artificial intelligence-powered eye care platform.
The dual achievement positions the company to accelerate market adoption of its technology, which enables ophthalmologists and optometrists to conduct critical diagnostic tests, particularly visual field examinations, with greater efficiency and improved patient experience.
"Achieving these milestones marks a proud moment for our organization," said Dr. Sarhan, CEO of RetinaLogik (搜索). "We've developed a solution that not only makes eye care more efficient but also more affordable and accessible. With the support of our investors and partners, we're excited to continue growing and improving the future of eye care for everyone."
Revolutionary Technology Reduces Costs and Improves Accessibility
The RetinaLogik (搜索) platform utilizes a portable VR headset to conduct comprehensive eye examinations, significantly reducing both testing time and equipment expenses. According to company data, the system can decrease upfront costs by as much as 90% compared to conventional eye care equipment.
The device has received multiple certifications, including ISO-13485 and MDSAP certification, alongside FDA registration in the United States. These regulatory achievements underscore the platform's clinical reliability and safety profile.
A key feature of the technology is its multilingual support capability, which helps overcome communication barriers in clinical settings—a particularly valuable asset in diverse patient populations.
Strong Investor Support Fuels Expansion
The funding round attracted significant interest from both existing and new investors, reflecting confidence in RetinaLogik (搜索)'s market potential and technological innovation.
"We have proudly supported the RetinaLogik (搜索) team since their earliest stages and are thrilled to deepen our commitment by doubling down on our investment in the company," said Nikhi, Operating Partner at UCeed Funds (搜索). "Over the past two years, the RetinaLogik team has built a groundbreaking VR platform that delivers unparalleled clinical reliability for functional eye exams."
Spring Impact Capital (搜索) co-led the investment round, with Managing Partner Graham Day noting: "Spring Impact Capital is proud to have co-led this round for RetinaLogik (搜索), which is proving strong market demand for its product. By enhancing access to quality eye care diagnostics and improving clinic efficiency, they are set to make a meaningful impact on communities while achieving commercial success."
Government Support Highlights Regional Innovation
The company's development has been bolstered by support from Alberta Innovates (搜索) through the Accelerating Innovations into CarE (AICE) program, demonstrating the province's commitment to healthcare technology advancement.
"Alberta Innovates (搜索) congratulates RetinaLogik (搜索) on obtaining its Health Canada Class II licence through support from the Accelerating Innovations into CarE program," said Trevor Lynn, Vice President of Health at Alberta Innovates. "This accomplishment is an example of Alberta's success commercializing health innovation to improve the patient experience and enable easier patient care access in the community."
Addressing Critical Needs in Eye Care
Vision disorders represent a significant healthcare challenge globally. Early detection of conditions such as glaucoma (搜索), macular degeneration (搜索), and diabetic retinopathy (搜索) is crucial for preventing irreversible vision loss, yet access to specialized diagnostic equipment remains limited in many regions.
RetinaLogik (搜索)'s platform addresses these challenges by making sophisticated diagnostic capabilities more accessible and affordable for a wider range of healthcare providers. The portable nature of the technology also opens possibilities for expanded screening programs in underserved communities.
With the new funding and regulatory approval, RetinaLogik (搜索) plans to expand adoption of its platform throughout North America and eventually to international markets. The company's focus remains on enabling earlier detection and treatment of vision-threatening conditions to improve patient outcomes and prevent vision loss.
For healthcare facilities facing budget constraints or space limitations, the RetinaLogik (搜索) system offers a compelling alternative to traditional equipment that typically requires dedicated rooms and substantial capital investment.